These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

117 related articles for article (PubMed ID: 21830727)

  • 21. Biphasic skin reactions during telaprevir-based therapy of Japanese patients infected with hepatitis C virus.
    Kishi A; Hayashi N; Ohara K; Aoki K; Yamada I; Ikeda K; Kumada H
    J Am Acad Dermatol; 2014 Mar; 70(3):584-6. PubMed ID: 24528908
    [No Abstract]   [Full Text] [Related]  

  • 22. The efficacy and safety of telaprevir - a new protease inhibitor against hepatitis C virus.
    Gentile I; Carleo MA; Borgia F; Castaldo G; Borgia G
    Expert Opin Investig Drugs; 2010 Jan; 19(1):151-9. PubMed ID: 20001560
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Ribavirin in chronic hepatitis C: past and future.
    Loustaud-Ratti V; Rousseau A; Marquet P; Denis F; Alain S
    Expert Rev Anti Infect Ther; 2009 Apr; 7(3):249-53. PubMed ID: 19344238
    [No Abstract]   [Full Text] [Related]  

  • 24. Sustained virological response in a patient with chronic hepatitis C treated by monotherapy with the NS3-4A protease inhibitor telaprevir.
    Suzuki F; Suzuki Y; Akuta N; Sezaki H; Yatsuji H; Arase Y; Hirakawa M; Kawamura Y; Hosaka T; Kobayashi M; Saito S; Ikeda K; Kobayashi M; Watahiki S; Mineta R; Iwasaki S; Kumada H
    J Clin Virol; 2010 Jan; 47(1):76-8. PubMed ID: 19857995
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Tailoring the length of antiviral treatment for hepatitis C.
    Mangia A; Andriulli A
    Gut; 2010 Jan; 59(1):1-5. PubMed ID: 20007952
    [No Abstract]   [Full Text] [Related]  

  • 26. Short treatment to patients with genotype 2 or 3.
    Dalgard O; Mangia A
    Hepatology; 2008 Aug; 48(2):694. PubMed ID: 18666251
    [No Abstract]   [Full Text] [Related]  

  • 27. Rapid virological response in hepatitis C virus genotype 1 and early ribavirin exposure.
    Dai CY; Chuang WL; Huang JF; Hsieh MY; Yu ML
    Hepatology; 2008 Aug; 48(2):692-3; author reply 693-4. PubMed ID: 18666250
    [No Abstract]   [Full Text] [Related]  

  • 28. Telaprevir activity in treatment-naive patients infected with hepatitis C virus genotype 4.
    Sefcik RK; Bichoupan K; Martel-Laferrière V; Odin JA; Liu LU; Perumalswami P; Bansal M; Dieterich DT; Ahmad J; Schiano TD; Branch AD
    J Infect Dis; 2014 Dec; 210(11):1855-6. PubMed ID: 24970848
    [No Abstract]   [Full Text] [Related]  

  • 29. A major advance in treating hepatitis C.
    Johns Hopkins Med Lett Health After 50; 2011 Dec; 23(10):6. PubMed ID: 22216468
    [No Abstract]   [Full Text] [Related]  

  • 30. [Similar poor response in genotype 4 chronic Hepatitis C treatment with interferon and ribavirin compared with genotype 1 treatment].
    Pérez Mota A; Graus J; García Flores MA; Blanco M; Pérez-Muñoz C; Villalgordo C; Rodero R
    Rev Esp Enferm Dig; 2003 Mar; 95(3):238-9. PubMed ID: 12760714
    [No Abstract]   [Full Text] [Related]  

  • 31. A pilot study of combination therapy with initial high-dose interferon and amantadine hydrochloride for patients with chronic hepatitis C with the genotype 1b virus.
    Uyama H; Enomoto H; Kishima Y; Yamamoto M; Yoshida K; Okuda Y; Hirotani T; Kuroda T; Ito H; Matsuda M; Terabayashi M; Noguchi S; Kawase I; Nakamura H
    Hepatogastroenterology; 2003; 50(54):2112-6. PubMed ID: 14696476
    [TBL] [Abstract][Full Text] [Related]  

  • 32. [Hepatitis C: therapeutic perspectives].
    Trépo C
    Gastroenterol Clin Biol; 2002 Apr; 26 Spec No 2():B297-302. PubMed ID: 12180304
    [No Abstract]   [Full Text] [Related]  

  • 33. [Current Guidelines for treatment of hepatitis C. The eradication of HCV as a goal].
    Sarrazin C; Zeuzem S
    Pharm Unserer Zeit; 2011 Jan; 40(1):52-9. PubMed ID: 21194083
    [No Abstract]   [Full Text] [Related]  

  • 34. [Treatment of patients with chronic hepatitis C virus infection and normal transaminases].
    Serfaty L
    Gastroenterol Clin Biol; 2002 Apr; 26 Spec No 2():B202-5. PubMed ID: 12180289
    [No Abstract]   [Full Text] [Related]  

  • 35. Interim results presented at EASL from PROVE 1 clinical trial of investigational drug telaprevir in patients with genotype 1 hepatitis C.
    Lang L
    Gastroenterology; 2007 Jun; 132(7):2283-4. PubMed ID: 17570199
    [No Abstract]   [Full Text] [Related]  

  • 36. [Treatment of hepatitis C in intravenous drug users].
    Filoche B
    Gastroenterol Clin Biol; 2002 Apr; 26 Spec No 2():B252-6. PubMed ID: 12180298
    [No Abstract]   [Full Text] [Related]  

  • 37. Clearance duration as a predictor of sustained viral response in patients with chronic hepatitis C virus genotype 1.
    Shenoy M; Levin J; Said A; Striker R
    J Infect Dis; 2005 Jun; 191(11):1993-5; 1995-6. PubMed ID: 15871137
    [No Abstract]   [Full Text] [Related]  

  • 38. Influence of hepatitis C virus (HCV) genotype, HCV RNA load, and alanine aminotransferase level on reduction of HCV RNA after a single administration of interferon-alpha.
    Antonelli G; Riva E; Maggi F; Vatteroni ML; Simeoni E
    J Infect Dis; 1999 Oct; 180(4):1411-2. PubMed ID: 10479188
    [No Abstract]   [Full Text] [Related]  

  • 39. [Recommendations for the treatment of chronic genotype 1 hepatitis C virus infection].
    Silva MO; Ridruejo E; Galdame O; Bessone F; Colombato L; Daruich J; Fainboim H; Fassio E; Fay F; Frider B; Gadano A; Galoppo MC; González J; Tanno H; Terg R; Villamil F; ;
    Acta Gastroenterol Latinoam; 2012 Sep; 42(3):234-49. PubMed ID: 23214356
    [No Abstract]   [Full Text] [Related]  

  • 40. Severe cutaneous eruptions on telaprevir.
    Chen ST; Wu PA
    J Hepatol; 2012 Aug; 57(2):470-2. PubMed ID: 22387663
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.